[1]Smith;Dezeny;Douglas[JournalofPharmaceuticalSciences,1990,vol.79,#8,p.732-740]
[1]Smith;Dezeny;Douglas[JournalofPharmaceuticalSciences,1990,vol.79,#8,p.732-740]
[1]Smith;Dezeny;Douglas[JournalofPharmaceuticalSciences,1990,vol.79,#8,p.732-740]
[1]Smith;Dezeny;Douglas[JournalofPharmaceuticalSciences,1990,vol.79,#8,p.732-740]
[1]Mendez;Alemany;Martin-Villacorta[ChemicalandPharmaceuticalBulletin,1992,vol.40,#12,p.3228-3233]
[2]Gadallah,MohamedI.;Ali,HassanRefatH.;Askal,HassanF.;Saleh,GamalA.[JournalofMolecularLiquids,2019,vol.276,p.705-713]
Title: Johann Motsch, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis. 2020 Apr 15;70(9):1799-1808.
Title: F P Tally, et al. In vitro activity of N-formimidoyl thienamycin (MK0787). Antimicrob Agents Chemother. 1980 Oct;18(4):642-4.
Title: Wang Hengzhuang, et al. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother. 2012 May;56(5):2683-90.
